Mocetinostat With Ipilimumab and Nivolumab for Unresectable Stage III/IV Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma
Melanoma Res. 2022 Oct 01;32(5)324-333, JS Weber, BA Levinson, AS Laino, AC Pavlick, DM WoodsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.